The Joint Corp.
NASDAQ:JYNTMedical - Care Facilities
+$0.17 today
- Market cap
- $91.03M
- Beta
- 1.10
- P/E (TTM)
- 40.7
- EPS (TTM)
- $0.23
Volume 0.05M
Average 0.07M
JYNT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
The Joint Corp.NASDAQ: JYNT
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures dips below year-ago levels
Q1 FY2026 capital expenditures of $234.6K (cash outflow) fell 29.2% year over year, behind the +25.4% change in trailing-twelve-month capital expenditures. Sequentially, it fell 32.9% from the prior quarter. Over 3 fiscal years it compounded at -36.6% a year.
Context
- Capital expenditures amounted to 2.7% of revenue in FY2025, up 0.5 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -29.2% toward the trailing-twelve-month pace of +25.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (1.5M) USD
- Year-over-year change
- -26.8%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.5M) | -26.8% |
| FY2024 | 2024-12-31 | (1.19M) | +76.3% |
| FY2023 | 2023-12-31 | (5M) | +15.3% |
| FY2022 | 2022-12-31 | (5.9M) | +15.6% |
| FY2021 | 2021-12-31 | (6.99M) | — |
Capital Expenditures vs competitors
How JYNT compares with its peers on the latest reported figures
- JYNT's LTM Mar 2026 capital expenditures of $1.41M is the 4th largest of the 11 companies compared; the peer median is $828K.
- Its year-over-year change of +25.4% is the 6th highest of 10, against a peer median of +50.8%.
- Capital expenditures amounts to 2.5% of revenue for JYNT, versus a peer median of 4.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $430.32B | +6838351.8% | +10.6% | 142623.8% | |
| LTM Mar 2026 | $186.01M | +82077.2% | — | 46866.7% | |
| LTM Mar 2026 | $4.74M | -37.0% | +39.7% | 2.5% | |
| LTM Mar 2026 | $1.41M | +25.4% | -36.6% | 2.5% | |
| LTM Mar 2026 | $1.12M | +50.8% | +3.3% | 2.0% | |
| LTM Mar 2026 | $925K | -15.8% | -49.9% | 2.7% | |
| LTM Mar 2026 | $731K | +86.5% | -2.8% | 1282.5% | |
| LTM Mar 2026 | $608K | -89.3% | -12.0% | 0.5% | |
| LTM Mar 2026 | $452.02K | — | -62.0% | — | |
| LTM Mar 2026 | $319K | -54.6% | -39.9% | 6.2% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| Peer median (excluding JYNT) | $828K | +50.8% | -7.4% | 4.5% | |
Competitors are the stored peer set for JYNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.57M | 626.71K | (9.75M) | (8.53M) | 2.91M |
| Depreciation & Amortization | 3.92M | 6.65M | 8.58M | 4.72M | 1.71M |
| Deferred Income Tax | (1.78M) | (441.35K) | 10.9M | (55.56K) | 93.07K |
| Stock-Based Compensation | 1.06M | 1.27M | 1.74M | 1.68M | 1.3M |
| Change in Working Capital | 3.09M | (238.06K) | 798.62K | 1.1M | (9.56M) |
| Accounts Receivables | (1.64M) | (154.67K) | 192.35K | (1.65M) | 1.53M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (14.37K) | 818.27K | (1.38M) | 68.26K | (391.13K) |
| Other Working Capital | 4.74M | (901.65K) | 1.99M | 2.68M | (10.7M) |
| Other Non-Cash Items | (7.77K) | 341.68K | 2.41M | 10.5M | 5.39M |
| Operating Cash Flow | 13.84M | 8.21M | 14.68M | 9.42M | 1.84M |
| Capital Expenditures | (6.99M) | (5.9M) | (5M) | (1.19M) | (1.5M) |
| Acquisitions (Net) | (5.77M) | (12.11M) | (1.19M) | 554.1K | 7.78M |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 105.2K | 0 | 0 | 0 |
| Investing Cash Flow | (12.75M) | (17.9M) | (6.19M) | (631.55K) | 6.27M |
| Debt Repayment | (2.81M) | (49.86K) | (24.43K) | (2.03M) | (4.35K) |
| Common Stock Issued | 0 | 0 | 202.39K | 33.71K | 1.52M |
| Common Stock Repurchased | 0 | (5.8K) | (3.83K) | (9.58K) | (11.32M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 811.59K | 384.27K | 0 | 0 | 0 |
| Financing Cash Flow | (2M) | 328.61K | 174.12K | (2M) | (9.81M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (907.29K) | (9.36M) | 8.66M | 6.78M | (1.69M) |
| Free Cash Flow | 6.85M | 2.31M | 9.68M | 8.23M | 334.72K |
The Joint Corp.
NASDAQ:JYNT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.